Targeting barriers to wider use of trimodality therapy in localized muscle invasive bladder cancer

Radical cystectomy with bilateral pelvic lymphadenectomy and trimodality bladder-sparing therapy or TMT, are both curative options for patients with nonmetastatic muscle invasive bladder cancer. Patients should be afforded the opportunity for a multidisciplinary evaluation with equipoise in discussing these options for eligible patients. We discuss the barriers to broader acceptance and utilization of TMT and encourage support of clinical trials of TMT. (C) 2020 Elsevier Inc. All rights reserved.

Automated summary

Radical cystectomy with bilateral pelvic lymphadenectomy and trimodality bladder-sparing therapy are both effective treatment options for patients with nonmetastatic muscle invasive bladder cancer. Multidisciplinary evaluation and unbiased discussion should be provided to eligible patients. The barriers to broader acceptance and utilization of trimodality bladder-sparing therapy are discussed, and support for clinical trials is encouraged.